Results 51 to 60 of about 427,029 (392)

Targeting PI3Kδ and PI3Kγ signalling disrupts human AML survival and bone marrow stromal cell mediated protection [PDF]

, 2016
Phosphoinositide-3-kinase (PI3K) is an enzyme group, known to regulate key survival pathways in acute myeloid leukaemia (AML). It generates phosphatidylinositol-3,4,5-triphosphate, which provides a membrane docking site for protein kinaseB activation ...
Alves, Arcaro, Asou, Bouscary, Bouscary, Bouscary, Bowles, Carroll, Carroll, DiPersio, Druker, Esmaeili-Mahani, Finan, Gandhi, Giese, Gilliland, Hirsch, Johnson, Jordan, Kahl, Khwaja, Khwaja, Ko, Konopleva, MacEwan, MacEwan, Niitsu, Pettitt, Pocock, Preudhomme, Recher, Ronnstrand, Rushworth, Solary, Ulrich, Wei, Wymann, Wymann   +37 more
core   +1 more source

Chronic lymphocytic leukemia developing in a case of chronic myelogenous leukemia - accelerated phase: A rare case with review of the literature

Indian Journal of Pathology and Microbiology, 2013
Chronic myelogenous leukemia (CML) and chronic lymphocytic leukemia (CLL) are two different and common hematological neoplasms. Their coexistence is rare, especially CLL developing in a patient of CML. Till date, only a few cases are reported and all had
Narender Kumar, Jasmina Ahluwalia, Pankaj Malhotra, Man Updesh Singh Sachdeva   +3 more
doaj   +1 more source

Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial

Leukemia, 2016
In the phase 3 Evaluating Nilotinib Efficacy and Safety in Clinical Trials–Newly Diagnosed Patients (ENESTnd) study, nilotinib resulted in earlier and higher response rates and a lower risk of progression to accelerated phase/blast crisis (AP/BC) than ...
A. Hochhaus, G. Saglio, T. Hughes, R. Larson, Dong-Kee Kim, S. Issaragrisil, P. Coutre, G. Étienne, P. Dorlhiac-Llacer, R. Clark, I. Flinn, H. Nakamae, B. Donohue, W. Deng, D. Dalal, H. Menssen, H. Kantarjian   +16 more
semanticscholar   +1 more source

Reciprocal t(9;22) ABL/BCR fusion proteins: leukemogenic potential and effects on B cell commitment [PDF]

, 2009
Background: t(9;22) is a balanced translocation, and the chromosome 22 breakpoints (Philadelphia chromosome – Ph+) determine formation of different fusion genes that are associated with either Ph+ acute lymphatic leukemia (Ph+ ALL) or chronic myeloid ...
Henschler, Reinhard, Moore, Malcolm A. S., Oancea, Claudia, Ruthardt, Martin, Zheng, Xiaomin   +4 more
core   +9 more sources

Chronic myeloid leukemia: 2025 update on diagnosis, therapy, and monitoring

American journal of hematology/oncology
Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm with an annual incidence of two cases/100 000. It accounts for approximately 15% of newly diagnosed cases of leukemia in adults.
E. Jabbour, H. Kantarjian
semanticscholar   +1 more source

Dasatinib discontinuation in patients with chronic-phase chronic myeloid leukemia and stable deep molecular response: the DASFREE study

Leukemia and Lymphoma, 2020
Treatment-free remission (TFR) in patients with chronic myeloid leukemia in chronic phase (CML-CP) is considered a feasible option, especially with the ability of second-generation tyrosine kinase inhibitors to induce higher rates of sustained deep ...
N. Shah, V. García‐Gutiérrez, A. Jiménez-Velasco, Sarah M. Larson, S. Saussele, D. Réa, F. Mahon, M. Levy, M. Gómez-Casares, F. Pane, F. Nicolini, M. Mauro, O. Sy, P. Martín-Regueira, J. Lipton   +14 more
semanticscholar   +1 more source

Management of imatinib-resistant CML patients [PDF]

, 2007
Imatinib has had marked impact on outcomes in chronic myelogenous leukemia (CML) patients for all stages of the disease and is endorsed by international treatment guidelines as the first line option.
Branford S, Burger H, Burgess MR, Cortes J, Crossman LC, Donato NJ, Druker BJ, Gambacorti-Passerini C, Giles F, Hochhaus A, Hughes TP, Iacobucci I, Kantarjian H, Lahaye T, Mahon FX, Melo JV, O'Hare T, Quintas-Cardama A, Rousselot P, Sleijfer S, Soverini S, Weisberg E   +21 more
core   +1 more source

Cardiovascular Toxicity of Tyrosine Kinase Inhibitors Used in Chronic Myeloid Leukemia: An Analysis of the FDA Adverse Event Reporting System Database (FAERS)

Cancers, 2020
Tyrosine kinase inhibitors (TKIs), the treatment of choice for chronic myeloid leukemia (CML), can be associated to cardiovascular (CV) adverse events (AEs).
S. Cirmi, Asmae El Abd, L. Létinier, M. Navarra, F. Salvo   +4 more
semanticscholar   +1 more source

Hematopoietic (stem) cells—The elixir of life?

FEBS Letters, EarlyView.
The aging of HSCs (hematopoietic stem cells) and the blood system leads to the decline of other organs. Rejuvenating aged HSCs improves the function of the blood system, slowing the aging of the heart, kidney, brain, and liver, and the occurrence of age‐related diseases.
Emilie L. Cerezo, Jonah Anderson, Emilie Dinh Vedrenne, Noël Yeh Martín, Jette Lengefeld   +4 more
wiley   +1 more source

Direct admission to the intensive care unit from the emergency department and mortality in critically ill hematology patients [PDF]

, 2019
Background: The aim of this study was to assess the benefit of direct ICU admission from the emergency department (ED) compared to admission from wards, in patients with hematological malignancies requiring critical care.
Azoulay, Elie, Benoit, Dominique, Bruneel, Fabrice, Chevret, Sylvie, Demoule, Alexandre, Kouatchet, Achille, Lebert, Christine, Lemiale, Virginie, Meert, Anne-Pascale, Mirouse, Adrien, Mokart, Djamel, Nyunga, Martine, Perez, Pierre, Peyrony, Olivier, Pène, Frédéric   +14 more
core   +2 more sources